Abu Dhabi’s (DoH) Policy on Assisted Reproductive Services

By Staff Writer

February 17, 2023

Understanding THIQA’s Policy on Assisted Reproductive Services

THIQA’s policy outlines the eligibility criteria, benefits, and reimbursement packages for Assisted Reproductive Techniques (ART) in Abu Dhabi. It is not a clinical management guideline, but rather a framework to ensure eligible patients in need of ART treatments receive coverage based on evidence-based medical criteria.

Determining Medical Necessity in Assisted Reproductive Treatments

THIQA covers Assisted Reproductive treatments deemed medically necessary. This could be due to a couple trying for pregnancy for at least a year, or one or both individuals diagnosed with infertility problems. Infertility can also be diagnosed prior to one year if there are features or findings indicative of subfertility, such as oligo or amenorrhea, history of pelvic infection, or abnormality in semen parameters.

Eligibility and Covered Services

The preferred age range for women seeking fertility is between 18-47 years. Exceptions apply for fertility preservation in female patients diagnosed with cancer. The Body Mass Index (BMI) eligibility range is from 19-40. Covered services include treatment, oocyte and embryo cryopreservation, transfer of embryos, medications, in vitro fertilisation (IVF), and genetic investigations.

The Future of Assisted Reproductive Services

The policy is a testament to the commitment of THIQA and other life sciences consulting firms to provide value-based healthcare. With advancements in artificial intelligence consulting services, we can expect more personalised and effective treatments in the future.

 

Reference url

Recent Posts

Publication Delays Impact Careers of Early-Career Researchers

By João L. Carapinha

May 19, 2025

The article “Dear editors, your publication delays are damaging our careers” by Chia-Hsuan Hsu highlights how publication delays hurt careers, especially for early-career researchers. With publication records key for jobs and tenure, slow editorial processes stall academic progress. The author sh...
Hepatitis C Investment Impact: Maximizing Health and Economic Returns in China

By João L. Carapinha

May 14, 2025

The economic ramifications of hepatitis C (HCV) are staggering. Estimates suggest the disease could impose a $1.17 trillion burden on China from 2023 to 2050. This is the crux of the hepatitis C investment impact article we cover below, meeting WHO's 2030 HCV diagnosis and treatment targets requi...
Implementing Health Technology Assessment in Oman

By João L. Carapinha

May 6, 2025

A recent article titled "A roadmap towards implementing health technology assessment in Oman" outlines a strategy for integrating health technology assessment in Oman into the healthcare system over the next decade. This initiative aims to improve resource allocation and facilita...